Blood Res 2018; 53(1): 35-40
Splenic myeloid metaplasia in warm autoimmune hemolytic anemia (wAIHA): a retrospective study
Víctor Manuel Anguiano-Álvarez1, Alonso Hernández-Company1, Nashla Hamdan-Pérez2, Daniel Montante-M3, Diego A. Zúñiga-Tamayo3, Sergio Rodríguez-Rodríguez1, Alan Pomerantz1, Elena J. Tuna-Aguilar1
1Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 2Médica Sur Foundation and Clinic, 3Pathology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, México City, México
Correspondence to: Víctor Manuel Anguiano-Álvarez, M.D. Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Col. Belisario Domínguez Sección XVI, CP 14080, Tlalpan, México City, México E-mail:
Received: May 23, 2017; Revised: August 6, 2017; Accepted: September 22, 2017; Published online: March 31, 2018.
© The Korean Journal of Hematology. All rights reserved.

Background Splenic myeloid metaplasia (SMM) is a kind of extramedullary hematopoiesis, whereas its clinical significance in wAIHA remains unclear. The aim of this study is evaluating the frequency and clinical characteristics of SMM, compared with splenic-congestion (SC). Methods We included patients with wAIHA treated in a Mexican tertiary hospital between January 1992 and December 2015. All patients received steroids as first-line treatment and splenectomy as second-line treatment. Results Among the thirty-six splenectomized patients, 15 (41.6%) and 21 (58.4%) were diagnosed as SMM and SC, respectively. No differences were found in clinical characteristics between two groups. SMM patients showed lower platelet count (147×109/L vs. 240×109/L, P=0.02) and higher presence of anti-dsDNA antibodies (40% vs. 4.7%, P=0.01) than SC patients. Although the complete response (CR) rate with first-line treatment was lower in SMM patients (13.3% vs. 47.6%; P=0.04), post-splenectomy median disease-free-survival (DFS) was longer (16.2 mo vs. 5.1 mo; P=0.19). Univariate/multivariate analysis showed that achieving CR during first-line treatment (OR 0.3, 95% CI: 0.03‒0.94, P=0.03) and higher platelet count (OR 0.99, 95% CI: 0.98‒0.99, P=0.03) were protective factors for SMM; and anti-dsDNA titer higher than 9.6 IU/dL was a risk factor for SMM (OR 2.76, 95% CI: 1.48‒5.14, P<0.001). Conclusion The wAIHA patients with SMM have different biological profiles with those without SMM. This study is the first trial evaluating the significance of histopathological spleen findings and their association with rheumatologic profile.
Keywords: Warm autoimmune hemolytic anemia, Splenic myeloid metaplasia, Splenic-congestion, Extramedullary hematopoiesis


This Article

Current Issue


Indexed/Covered by

Today : 16  /
Total : 79,131